positive regulation of interleukin-4-mediated signaling pathway
Definition
Target type: biologicalprocess
Any process that activates or increases the frequency, rate or extent of interleukin-4-mediated signaling pathway. [GOC:TermGenie, PMID:17210636]
Positive regulation of interleukin-4-mediated signaling pathway involves a complex cascade of events that ultimately lead to the activation of downstream target genes. The process begins with the binding of interleukin-4 (IL-4) to its specific receptor, IL-4R, on the surface of target cells. This binding event triggers a series of intracellular signaling events that culminate in the activation of transcription factors such as STAT6. The IL-4R is a heterodimer composed of two subunits, IL-4Rα and γc. Upon IL-4 binding, the IL-4Rα subunit recruits Janus kinase 3 (JAK3), a tyrosine kinase, which is associated with the γc subunit. JAK3 then phosphorylates tyrosine residues on the cytoplasmic tails of IL-4Rα and γc, creating docking sites for the recruitment of STAT6. STAT6 is a transcription factor that plays a critical role in the regulation of IL-4-mediated gene expression. Once recruited to the receptor complex, STAT6 is phosphorylated by JAK3. This phosphorylation event leads to the dimerization of STAT6 and its subsequent translocation to the nucleus. In the nucleus, STAT6 binds to specific DNA sequences known as IL-4 response elements (IL-4REs) in the promoters of target genes, leading to their transcriptional activation. These target genes are involved in various biological processes including immune response, cell growth, and development. The positive regulation of this pathway is essential for the development and function of the immune system. It plays a crucial role in the differentiation of T helper cells into Th2 cells, which are responsible for the production of IL-4 and other cytokines that are important for humoral immunity and allergic responses. Moreover, IL-4 signaling also contributes to the regulation of B cell development and antibody production.'
"
Proteins (1)
| Protein | Definition | Taxonomy |
|---|---|---|
| Protein mono-ADP-ribosyltransferase PARP14 | A protein mono-ADP-ribosyltransferase PARP14 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q460N5] | Homo sapiens (human) |
Compounds (7)
| Compound | Definition | Classes | Roles |
|---|---|---|---|
| pj-34 | PJ34 : A member of the class of phenanthridines that is 5,6-dihydrophenanthridine substituted at positions 2 and 6 by (N,N-dimethylglycyl)amino and oxo groups, respectively. It is a potent inhibitor of poly(ADP-ribose) polymerases PARP1 and PARP2 (IC50 of 110 nM and 86 nM, respectively) and exhibits anti-cancer, cardioprotective and neuroprotective properties. | phenanthridines; secondary carboxamide; tertiary amino compound | angiogenesis inhibitor; anti-inflammatory agent; antiatherosclerotic agent; antineoplastic agent; apoptosis inducer; cardioprotective agent; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; neuroprotective agent |
| 4-Methoxybenzamide | benzamides | ||
| rucaparib | AG14447: Poly(ADP-ribose) polymerase inhibitor; structure in first source | azepinoindole; caprolactams; organofluorine compound; secondary amino compound | antineoplastic agent; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor |
| veliparib | benzimidazoles | EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor | |
| niraparib | niraparib : A 2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamide that has S-configuration. It is a potent inhibitor of PARP1 and PARP2 (IC50 of 3.8 and 2.1 nM, respectively) and approved as a first-line maintenance treatment for women with advanced ovarian cancer after responding to platinum-based chemotherapy. niraparib: structure in first source | 2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamide | antineoplastic agent; apoptosis inducer; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; radiosensitizing agent |
| xav939 | XAV939 : A thiopyranopyrimidine in which a 7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine skeleton is substituted at C-4 by a hydroxy group and at C-2 by a para-(trifluoromethyl)phenyl group. XAV939: selectively inhibits beta-catenin-mediated transcription; structure in first source | (trifluoromethyl)benzenes; thiopyranopyrimidine | tankyrase inhibitor |
| bmn 673 | talazoparib: inhibits both PARP1 and PARP2; structure in first source |